Clinical trial · Interventional
Timely Ordering of Pharmacogenetic Testing
Timely Ordering of Pharmacogenetic Testing in Pediatric Oncology
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this trial is to learn if a machine learning (ML) model can help optimize drug therapy in the pediatric population. The main question\[s\] it aims to answer are whether a machine learning model predicting receipt of a targeted medication within the next three months: * Increases the offering of pharmacogenetic testing prior to receipt of a targeted medication * Increases the number of patients with pharmacogenetic results prior to receipt of a targeted medication * Increases the number of patients who have alteration in medication choice or dose based on pharmacogenetic results This trial only focuses on the prediction and provision of participants with a high-risk of receiving a medication with a pharmacogenetic indication in the next three months.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Machine Learning | — | UNRESOLVED | — |
| Pediatrics | — | UNRESOLVED | — |
| Precision Medicine | — | UNRESOLVED | — |
| Prediction Models | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ML-based intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- ML model
- description
- Participants predicted by an ML model to receive a "targeted medication" within three months following admission.
- interventionNames
- Other: ML-based intervention
Primary outcomes (1)
- measure
- Proportion of Patients with Pharmacogenetic Testing
- timeFrame
- Day 1 to 3 months
- description
- The primary outcome will be the proportion of patients with pharmacogenetic testing offered among those who receive a medication with a pharmacogenetic indication within three months of prediction time. Testing must be offered prior to receipt of the first targeted medication.
Secondary outcomes (2)
- measure
- Number of patients with pharmacogenetic results available prior to receipt of targeted medication
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 6 Months
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Inpatient at The Hospital for Sick Children * Between 6 months to 18 years old Exclusion Criteria: * Prior pharmacogenetic testing and/or prior receipt of a targeted medication * Current Intensive Care Unit (ICU) admission * Expected hospital discharge is prior to midnight on the day of admission
References
Publications (0)
Data not yet available